Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.58 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.50 |
| ▸ | OGT | O15294 | 1/20 | 0.50 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMO | O15229 | 1/20 | 0.47 |
| ▸ | NOS3 | P29474 | 3/20 | 0.44 |
| ▸ | NOS2 | P35228 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 2/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3774426 | 0.85 | NOS1 (0.58) | NOS1PDE3BPDE3AOGTCREBBP | |
| SCHEMBL15333188 | 0.82 | KIF11 (0.41) | NOS1PDE3BPDE3ACREBBPKDM4E | |
| SCHEMBL20564646 | 0.80 | NOS1 (0.51) | NOS1PDE3BPDE3AOGTCREBBP | |
| SCHEMBL17268195 | 0.80 | OGT (0.53) | NOS1PDE3BPDE3AOGTCREBBP | |
| Cyanide SCHEMBL22130088 | 0.76 | NOS1 (0.47) | NOS1PDE3BPDE3AOGTCREBBP | |
| SCHEMBL8128113 | 0.75 | NOS1 (0.54) | NOS1PDE3BPDE3AOGTCREBBP | |
| SCHEMBL17368453 | 0.75 | NOS1 (0.50) | NOS1PDE3BPDE3AOGTCREBBP | |
| SCHEMBL28854707 | 0.74 | NOS1 (0.53) | NOS1PDE3BPDE3AOGTCREBBP | |
| SCHEMBL1519891 | 0.73 | NOS1 (0.72) | NOS1PDE3BPDE3AOGTCREBBP | |
| SCHEMBL11597370 | 0.73 | NOS1 (0.61) | NOS1PDE3BPDE3AOGTCREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743175-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Aconcagua Bio, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026088071-A1 | SUBSTITUTED FUSED HETEROARYL LACTAM COMPOUNDS | PFIZER INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260042760-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | ACONCAGUA BIO INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12486269-B2 | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity | ACONCAGUA BIO, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250257067-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | ACONCAGUA BIO, INC. | 2025-08-14 | — | — | US | disclosed |
| US-20250051355-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2025015269-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| CN-116940562-A | Acetamido-phenylbenzamide derivatives and methods of use thereof | 希华医药有限公司 | 2023-10-24 | — | — | CN | disclosed |
| EP-4225745-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | Athenex, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20070148093-A1 | Non-terminal method of identifying anti-migraine compounds | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-20070148093-A1 | Non-terminal method of identifying anti-migraine compounds | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-20070148093-A1 | Non-terminal method of identifying anti-migraine compounds | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-7220862-B2 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220862-B2 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220862-B2 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| CN-1917921-A | Calcitonin gene related peptide receptor antagonists | BRISTOL MYERS SQUIBB CO (US) | 2007-02-21 | — | — | CN | disclosed |
| EP-1689493-A1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Pharma Company (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005065779-A1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20040204397-A1 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486269-B2 | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity | IAPP, GIPR, SCTR | NOS1 3640/4885PDE3B 1340/4885PDE3A 1465/4885 |
| US-20260042760-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | NPY1R, CALCRL, SCTR | NOS1 3331/4885PDE3B 2360/4885PDE3A 2327/4885 |
| US-20250257067-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | IAPP, GIPR, SCTR | NOS1 3640/4885PDE3B 1340/4885PDE3A 1465/4885 |
| US-20070148093-A1 | Non-terminal method of identifying anti-migraine compounds | VDAC1, HTR3B, FAAH | NOS1 734/4885PDE3B 439/4885PDE3A 524/4885 |
| US-20250051355-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | IAPP, GIPR, GPR119 | NOS1 4268/4885PDE3B 695/4885PDE3A 788/4885 |
| US-20040204397-A1 | Calcitonin gene related peptide receptor antagonists | CALCRL, CALCA, CALCR | NOS1 235/4885PDE3B 664/4885PDE3A 728/4885 |
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | SCTR, SSTR1, NPY1R | NOS1 4008/4885PDE3B 2184/4885PDE3A 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.